Abstract: Almost all optic neuropathies are untreatable, motivating the search for new therapies that address the final common pathway of optic nerve disease, retinal ganglion cell loss. These neuroprotective strategies have been primarily studied in glaucoma, the most common optic neuropathy, but increasing also tested at the laboratory and animal model level in nonglaucomatous optic neuropathies. More recently, several clinical trials, most of which are randomized, have begun to examine whether neuroprotection is efficacious in human optic nerve disease. Many of these trials are reviewed, along with the critical issues in the major areas of optic neuropathy, particularly the site of injury, the mechanism of axonal damage, and disease-specific features relevant to neuroprotection studies.
ANATOMY
To understand neuroprotective strategies for optic neuropathies, it is critical to understand the basic anatomy and functioning of the optic nerve and its afferent and efferent structures. Within the retina, the retinal ganglion cell sits in the innermost cellular layer. It receives input from bipolar cells and amacrine cells. The bipolar cells receive input from photoreceptors, and therefore the retinal ganglion cell is a third order neuron with respect to the rods and cones that actually receive visual input. Retinal ganglion cells extend their axons through the surface of the retina in the nerve fiber layer, make a 90-degree turn at the optic disc, and extend centrally through the intraorbital, intracanalicular, and intracranial optic nerve to several target areas. For visual perception, the most important target area is the lateral geniculate nucleus, which provides further computation and then sends axons to the visual cortex. Other target areas include those responsible for the pupils (the pretectal nuclei), unconscious visual orientation (the superior colliculi), and the sleep-wake cycle (the suprachiasmatic nucleus of the hypothalamus). In higher species, the retinal ganglion cell and its axons do not regenerate when there has been damage. Lower species, such as goldfish and frogs, are an exception to this general rule. It is the fact that the loss of retinal ganglion cells in higher animals is a consequence of optic nerve injury that explains the nature of the clinical findings that there is little recovery after complete injury to these cells, along with the pressing need to find new strategies such as those involved in neuroprotection and no recovery.
DEFINITIONS
Neuroprotection is a broad term used to cover a variety of more specific therapeutic strategies related to neuronal disease. Neuroprotection is also a specific term related to preventing the loss of neurons and their connections when there is ongoing disease or future disease anticipated. In contrast to neuroprotection, the term neurorecovery is used to help improve visual function when there has been past damage.
Within neuroprotection, there is direct neuroprotection and indirect neuroprotection. Direct neuroprotection is the more classic form and is used when the treatment is relatively independent of the disease pathophysiology. In this case, the neuroprotective strategy is directed at neuronal cells or related cells such as astrocytes, glia, or both. Indirect neuroprotection is used to describe therapies that are related to the disease pathophysiology. For example, in the case of glaucoma, lowering the intraocular pressure is indirectly neuroprotective because it results in less disease progression and, therefore, lower rates of retinal ganglion cell loss. In the same way, a treatment for multiple sclerosis that decreases disease activity by modulating immune activity and thereby lowering the rate of exacerbations is indirectly neuroprotective, even though the therapy itself may not act on neuronal or glial cells.
Similarly, there are two types of neurorecovery.
Neuroenhancement covers a group of therapies directed at improving visual function where there has been a decrement due to past damage from the disease. The assumption is that the neuroenhancing therapy increases function using the current neuronal wiring but somehow increases activity for visual perception. 
DISEASES
Although no therapy that is directly neuroprotective has been approved by regulatory agencies for optic neuropathy, and only 1 class of therapy has been approved that is indirectly neuroprotective (lowering of intraocular pressure for glaucoma), there are many laboratories, organizations, and companies working on developing such therapies. This section will discuss some of the more common optic neuropathies and those aspects of neuroprotection that are relevant to each of them. The example of ischemic optic neuropathy will be discussed in depth as an exemplar of the issues involved in applying neuroprotective approaches to optic nerve disease.
Ischemic Optic Neuropathy

Background
Ischemic optic neuropathy has been called a "stroke of the optic nerve." In almost all cases it occurs at the level of the optic nerve head and is called anterior ischemic optic neuropathy (AION). There are 2 types of AION. Nonarteritic anterior ischemic optic neuropathy (NAION) is idiopathic and typically occurs in patients of middle age or older. It is also the most common acute optic neuropathy in that age group. The second type of AION is arteritic anterior ischemic optic neuropathy, typically associated with giant cell (temporal) arteritis. In contrast, posterior ischemic optic neuropathy (PION), where the damage occurs posterior to the optic nerve head, can be associated with giant cell arteritis but also blood loss or radiation. PION is far rarer than AION.
As with almost all optic neuropathies, there is no treatment for ischemic optic neuropathy; although when there is giant cell arteritis, corticosteroids are used to arrest or decrease the arteritic inflammation and preserve future vision.
Site of Injury
The site of injury of ischemic optic neuropathy depends on whether the disease is anterior or posterior. As mentioned previously, most patients have anterior disease and, therefore, the injury occurs at the optic nerve head at the level of the intrascleral optic nerve (ie, where the optic nerve traverses the sclera). With PION, the injury can occur anywhere along the course of the optic nerve, although it much less commonly involves the chiasm or tract. 4 In both AION and PION, therefore, the damage occurs at the level of the axon and not at the retinal ganglion cell body or its dendrites. As will be seen below, this axonal localization is a common feature for the site of injury of other optic neuropathies.
Mechanisms
The mechanism of ischemic optic neuropathy is controversial and is thought to be an ischemic injury, as suggested by the name. The exact cause of the ischemic insult is unclear. For the most common type, NAION, there seems to be a compartment syndrome, 5, 6 where the initial ischemia in an optic nerve within a tight scleral canal causes swelling, and with the swelling limited by the scleral ring, there is consequent increased ischemia. This cycle of edema and axonal injury continues, resulting in severe visual loss. The fact that many patients report that their visual loss is first noticed upon awakening led to the hypothesis that the initial ischemia could result from nocturnal hypotension, but this is controversial. The correlation of NAION with taking phosphodiesterase-5 inhibitors, undergoing spinal surgery, having diabetes, and a history of sleep apnea led to the hypothesis that there may be a role for a venous component to the initial infarct. 7 However, there is no clear explanation yet for the pathophysiology of this disease. In contrast, for AION there is excellent histological evidence of vasculitis within the walls of small and medium blood vessels throughout the extracranial vasculature.
Clinical Trials
Neuroprotection for ischemic optic neuropathy has been sought for many years. Johnson 8, 9 studied the role of levodopa and suggested improvement in chronic and recent-onset NAION patients with this drug. As with many other therapeutic trials of NAION, the results were controversial. 10 Wilhelm and colleagues 11 studied the alpha-2 agonist brimonidine in NAION in a trial that was relatively small and failed to show clear evidence of neuroprotection.
Quark Pharmaceuticals is performing an ongoing quadruple-masked randomized clinical trial of approximately 800 participants with acute NAION, who are given different intravitreal doses or sham injection of a silencing RNA (QPI-1007) against caspase 2, a critical component of the apoptosis pathway. The primary outcome measures are change in best-corrected visual acuity from baseline to month 12, along with safety and tolerability. Secondary measures include visual fields based on Humphrey standard automated perimetry. Participants are required to have their first episode of NAION within 14 days before drug administration or sham injection. As of July 2018 there were 89 study locations, but results are not available.
Regenera Pharma recently began enrollment of a quadruple-masked randomized clinical trial of a novel botanical-based drug (RPh201) in participants who had previous NAION with onset at least 1 year and not more than 5 years before enrollment. The primary outcome measure is the proportion of study eyes improving by 15 letters or more in best-corrected visual acuity, with secondary outcome measures including improvement in Humphrey standard automated perimetry. As of August 2018, there were 2 clinical sites listed on ClinicalTrials.gov for this study. typically low. Although the Ischemic Optic Neuropathy Decompression Trial showed that approximately 43% of participants see an improvement in visual acuity by 15 letters or more over 6 months of observation, 12 much of that improvement may be due to training effects. Patients with NAION and other causes of acute visual loss learn to use eccentric fixation over time. In a rigorously controlled trial where training effects are minimized by having ample opportunity for participants to learn to use eccentric fixation, baseline rates without treatment should theoretically show low rates of improvement. A low baseline rate of improvement should make ischemic optic neuropathy an excellent environment for studying a neuroprotective or neuroenhancing therapy that would potentially improve those rates.
Assessment of visual acuity is a frequently used outcome measure for clinical trials, and use of Early Treatment Diabetic Retinopathy Study charts or electronic visual acuity machines 13 has become well-established. Given that ischemic optic neuropathy itself is fairly common, enrollment is not very difficult. Finally, there is a pressing need for treatment given that the outcome in ischemic optic neuropathy is so poor. Furthermore, there is an approximately 15% chance that a patient with ischemic optic neuropathy will have involvement of the other eye within 5 years, making the potential value of a neuroprotective treatment even higher.
There are also disadvantages to ischemic optic neuropathy as a choice for neuroprotection studies. There is significant variability in the course and severity of the disease, and some patients improve greatly whereas others may significantly worsen. The acute nature of the disease and the short time between injury and retinal ganglion cell death mean that it is critical that patients enter the study rapidly after they are symptomatic.
Optic Neuritis and Other Inflammatory Optic Neuropathies
Background
The most common acute optic neuropathy is optic neuritis, an inflammatory disorder of the optic nerve that is frequently associated with or is a harbinger of multiple sclerosis. The natural history of optic neuritis is visual loss that takes place over a few days, with pain on eye movements, loss of color vision, central visual field loss, and decreased visual acuity. In most patients, the vision recovers over several weeks. Although visual acuity may return to normal, it is common for there to be some decrease in contrast sensitivity, and there is definite loss of retinal ganglion cells in the retinal nerve fiber layer. 14, 15 In some patients there is persistent poor visual acuity. Related to optic neuritis are other inflammatory neuropathies, including those caused by sarcoidosis, systemic lupus erythematosus, granulomatous polyangiitis, and a variety of disorders associated with corticosteroid dependency, including neuromyelitis optica spectrum disorder, chronic relapsing inflammatory optic neuropathy, and possibly paraneoplastic optic neuropathy, which has an inflammatory component.
Although the natural history of the most common inflammatory optic neuropathies includes recovery of vision, the fact that some disorders may have a poor prognosis has led to a search for neuroprotective treatments. As mentioned above, even those patients who recover functional vision with the more common optic neuritis variants may still have loss of retinal ganglion cell axons, as measured by optical coherence tomography.
Site of Injury
The site of injury in most cases of optic neuritis is retrobulbar (ie, posterior to the optic nerve head) in two thirds of patients and is at the optic nerve head, as evidenced by disc edema, in the other third. 16 In occasional cases, the injury may occur at the chiasm or even the tract. Either way, optic neuritis is, therefore, an axonal injury.
Mechanisms
The mechanism of optic neuritis is presumably related to dysregulation of the immune system, although much of the pathogenesis remains to be understood. Drugs that decrease the number of relapses of multiple sclerosis also decrease the number of attacks of optic neuritis. The fact that many inflammatory optic neuropathies are highly corticosteroid-dependent also points to a strong inflammatory component of the disease. Demyelination is a prominent component of the optic neuritis associated with multiple sclerosis, as evidenced by the marked slowing of visually evoked responses.
Clinical Trials
One of the first human studies of neuroprotection in optic neuritis was performed by Suhs and colleagues, 17 studying erythropoietin in acute optic neuritis. Participants were treated with erythropoietin or placebo, in addition to methylprednisolone. The primary outcome measure was the degree of retinal ganglion cell axon loss, as measured by thinning of the retinal nerve fiber layer. Treatment with erythropoietin decreased the amount of thinning by more than 50%, compared with placebo.
The Treatment of Optic Neuritis with Erythropoietin study is taking place at several centers in Germany, with both retinal nerve fiber layer thickness and low-contrast visual acuity as primary endpoints. A randomized trial of oral phenytoin versus placebo was performed in participants with acute optic neuritis, demonstrating less loss of retinal ganglion cell axons in the nerve fiber layer. 18 The use of retinal ganglion cell axonal loss as an endpoint in this and other studies is based on its clinical relevance in those with multiple episodes of optic neuritis or subclinical disease, along with its value as an objective measurement.
The RENEW study compared treatment with the monoclonal antibody opicinumab (anti-LINGO-1) versus placebo plus methylprednisolone in acute optic neuritis. 19 The rationale for the study was preclinical evidence for antibody to LINGO-1 improving remyelination. There were no significant differences between groups in remyelination, as assessed by the primary outcome measure of visual-evoked response latency in the intention-to-treat analysis, but there were some significant changes when studied with a per-protocol analysis.
Disease-Specific Features Relevant to Neuroprotection Studies
Optic neuritis is a difficult disease to study in neuroprotection clinical trials if conventional outcome measures such as high-contrast visual acuity or visual field are used, due to the high rate of recovery to normal in these measures. However, studies of neuroprotection in optic neuritis are easier if structural measures such as retinal nerve fiber layer thickness are used, or if more sensitive (and more relevant to contrast sensitivity) measures such as low-contrast visual acuity are endpoints. As with ischemic optic neuropathy, there is a great variability in the degree of initial improvement in visual function can be proven, it would likely be accepted as a clinically meaningful outcome measure by regulatory agencies.
CONCLUSIONS
In summary, optic neuropathies are excellent targets for neuroprotective and neurorecovery strategies. Although most published studies enrolled small numbers of participants, ongoing trials are powered at much more robust levels, and if successful, may result in the availability of approved therapies for these irreversibly blinding diseases.
visual loss in individual patients with optic neuritis. For the optic neuritis variants that have poor outcomes and severe vision loss, a more standard neuroprotection study would be able to detect a therapeutic effect, but the number of participants in such a trial would be low because diseases in this category are rare. On the other hand, the lack of good treatments implies a pressing need for neuroprotective therapies, and the rarity of such diseases would mean that regulatory agencies would be willing to provide an orphan designation, both of which would help in carrying out such trials.
Other Optic Neuropathies
In compressive optic neuropathy, once compression of the anterior visual pathways is detected, treatment is surgical removal of the mass, drug therapy in the case of prolactinomas, radiation for radiosensitive tumors, and/or chemotherapy. However, if a tumor cannot be removed surgically or if the compression is too great, then a neuroprotective approach might be useful. This would be of particular use in fast-growing tumors or pituitary apoplexy.
Infiltrative optic neuropathy, such as that resulting from optic nerve gliomas, can cause visual loss. The variability of the presentation makes such studies difficult. In most cases these tumors are difficult to eradicate because they are intrinsic to the nerve and, therefore, neuroprotective therapies might be useful.
Hereditary optic neuropathies such as Leber hereditary optic neuropathy or dominant optic atrophy can lead to significant vision loss. Idebenone was studied in a high-quality randomized clinical trial. 20 Although it did not meet its primary outcome measure, it did show significant effects in other outcome measures. A retrospective study performed in Italy with the same drug showed similar effects. 21 Brimonidine was studied for preventing second-eye involvement in Leber hereditary optic neuropathy, an outcome that is universal in patients who have single-eye involvement. 22 However, the study failed to show prevention of bilateral disease.
One of the most frequent toxic optic neuropathies occurs with ethambutol, an antibiotic frequently used in combination with 2-3 other drugs in patients with tuberculosis or other mycobacterial infections. It is conceivable that a neuroprotective drug could be studied in this setting and would be of great value in allowing use of ethambutol when multidrug treatments are needed for mycobacterial disease.
NEUROENHANCEMENT AND NEUROREGENERATION
Detecting improvement of visual function after the loss of vision from an optic neuropathy is neurorecovery, which can be studied when there are appropriate treatments based on preclinical research. The previously mentioned study of RPh201 in participants with previous NAION will test the detection of a neuroenhancing or neurodegenerative effect. Such studies are straightforward to design because a stable baseline can usually be obtained, eliminating learning effects, and because progression (which can be variable) is not the endpoint, the effects of the treatment can be studied in a relatively short amount of time. It is difficult to determine whether a drug is causing an enhancement of preexisting visual function circuitry, versus regenerating axons or increasing synaptic connectivity. Nonetheless, if significant
